Skip to content

Luteinizing hormone supplementation to OCP pretreatment GnRH antagonist protocol in normal responder patients: a randomized controlled trial.

Luteinizing hormone supplementation to OCP pretreatment GnRH antagonist protocol in normal responder patients: a randomized controlled trial.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IOR-15007659
Enrollment
Unknown
Registered
2015-12-27
Start date
2016-01-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

infertility

Interventions

1:oral contraceptive pretreatment, not use of LH
2:oral contraceptive pretreatment, supplement LH
3:decrease dose of oral contraceptive pretreatment, no use of LH
4:decrease dose of oral contraceptive pretreatment, supplement LH

Sponsors

Reproductive Center, First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 35 Years

Inclusion criteria

Inclusion criteria: 1. have two ovary; 2. regular menstruation cycle between 25 and 35 days; 3. age <=35 years; 4. serum basal follicle-stimulating hormone (FSH) concentration < 12 mIU/mL; 5. the first IVF-ET cycle and no treatment with gonadotrophins within 3 months before the study.

Exclusion criteria

Exclusion criteria: presence of polycystic ovarian syndrome (PCOS), endometriosis, uterine malformation, ovarian tumor, thyroid disease, Systemic Lupus Erythematosus, Preimplantation genetic diagnosis, repeated implantation failure, intrauterine adhesion, recurrent spontaneous abortion, chromosome abnormality, BMI >30 kg/m2, hyperlipidemia, hypertension, diabetes, Thrombotic diseases.

Design outcomes

Primary

MeasureTime frame
clinical pregnancy rate;implantation rate;

Secondary

MeasureTime frame
Gn dose;Gn days;oocyte number;used number of embryo;progesterone level in HCG day;

Countries

China

Contacts

Public ContactXu Yan-wen
xuyanwen@live.cn+86 13682213000

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026